Noonan syndrome: Relationships between genotype, growth, and growth factors

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 1, 2006, Pages 300-306

  Limal, Jean Marie ^a   Parfait, Béatrice ^b   Cabrol, Sylvie ^c   Bonnet, Damien ^d   Leheup, Bruno ^f   Lyonnet, Stanislas ^e   Vidaud, Michel ^b   Le Bouc, Yves ^c  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b Faculte de Pharmacie   (France)

^c ARMAND TROUSSEAU HOSPITAL   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; MAXOMAT; PROTEIN; PROTEIN PTPN11; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; BIRTH WEIGHT; BLOOD LEVEL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENOTYPE; GROWTH RETARDATION; HUMAN; MALE; MISSENSE MUTATION; NOONAN SYNDROME; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADOLESCENT; ANTHROPOMETRY; BIRTH WEIGHT; CARRIER PROTEINS; CHILD; DNA MUTATIONAL ANALYSIS; FEMALE; GENOTYPE; GLYCOPROTEINS; GROWTH; GROWTH DISORDERS; GROWTH HORMONE; GROWTH SUBSTANCES; HUMAN GROWTH HORMONE; HUMANS; INFANT, NEWBORN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MUTATION, MISSENSE; NOONAN SYNDROME; PROSPECTIVE STUDIES; PROTEIN-TYROSINE-PHOSPHATASE; PUBERTY; STIMULATION, CHEMICAL;

EID: 30344444283     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-0983     Document Type: Article

References (45)

1. Noonan JA 1968 Hypertelorism with Turner phenotype. A new syndrome with associated congenital heart disease. Am J Dis Child 116:373-380
2. Brady AF, Jamieson CR, van der Burgt I, Crosby AH, van Reen M, Kremer H, Mariman E, Patton MA, Jeffery S 1997 Further delineation of the critical region for Noonan syndrome on the long arm of chromosome 12. Eur J Hum Genet 5:336-337
3. van der Burgt I, Brunner HG 2000 Genetic heterogeneity in Noonan syndrome: evidence for an autosomal recessive form. Am J Med Genet 94:46-51
4. Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer MA, van der Burgt I, Crosby AH, Ion A, Jeffery S, Kalidas K, Patton MA, Kucherlapati RS, Gelb BD 2001 Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 29:465-468
5. Saenger P 2002 Noonan syndrome-certitude replaces conjecture. J Clin Endocrinol Metab 87:3527-3528 (Editorial)
6. Neel BG, Gu H, Pao L 2003 The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci 28:284-293
7. Hof P, Pluskey S, Dhe-Paganon S, Eck MJ, Schoelson SE 1998 Crystal structure of the tyrosine phosphatase SHP-2. Cell 92:441-450
8. Kosaki K, Suzuki T, Muroya K, Hasegawa T, Sato S, Matsuo N, Kosaki R, Nagai T, Hasegawa Y, Ogata T 2002 PTPN11 (protein-tyrosine phosphatase, non-receptor-type 11) mutations in seven Japanese patients with Noonan syndrome. J Clin Endocrinol Metab 87:3529-3533
9. Tartaglia M, Kalidas K, Shaw A, Song X, Musat DL, van der Burgt I, Brunner HG, Bertola DR, Crosby AH, Ion A, Kucherlapati RS, Jeffery S, Patton MA, Gelb BD 2002 PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet 70:1555-1563
10. Musante L, Kehl HG, Majewski F, Meinecke P, Schweiger S, Gillessen-Kaesbach G, Wieczorek D, Hinkel GK, Tinschert S, Hoeltzenbein M, Ropers HH, Kalscheuer VM 2003 Spectrum of mutations in PTPN11 and genotype-phenotype correlations in 96 patients with Noonan syndrome and five patients with cardio-facio-cutaneous syndrome. Eur J Hum Genet 11:201-206
11. Yoshida R, Hasegawa T, Hasegawa Y, Nagai T, Kinoshita E, Tanaka Y, Kanegane H, Ohyama K, Onishi T, Hanew K, Okuyama T, Horikawa R, Tanaka T, Ogata T 2004 Protein-tyrosine phosphatase, nonreceptor type 11 mutation analysis and clinical assessment in 45 patients with Noonan syndrome. J Clin Endocrinol Metab 89:3359-3364
12. Zenker M, Buheitel G, Rauch R, Koenig R, Bosse K, Kress W, Tietze HU, Doerr HG, Hofbeck M, Singer H, Reis A, Rauch A 2004 Genotype-phenotype correlations in Noonan syndrome. J Pediatr 144:368-374
13. Witt DR, Keena BA, Hall JG, Allanson JE 1986 Growth curves for height in Noonan syndrome. Clin Genet 30:150-153
14. Ranke MB, Heidemann P, Knupfer C, Enders H, Schmaltz AA, Bierich JR 1988 Noonan syndrome: growth and clinical manifestations in 144 cases. Eur J Pediatr 148:220-227
15. Patton MA 1994 Noonan syndrome: a review. Growth Genet Horm 10:1-3
16. Cotterill AM, McKeena WJ, Brady AF, Shardland M, Elsawi M, Yamada M, Camacho-Hübner C, Kelnar CJ, Dunger DB, Patton MA, Savage MO 1996 The short-term effects of growth hormone therapy on height velocity and cardiac ventricular wall thickness in children with Noonan syndrome. J Clin Endocrinol Metab 81:2291-2297
17. Tanaka K, Sato A, Naito T, Kuramochi K, Itabashi H, Takemura Y 1992 Noonan syndrome presenting growth hormone neurosecretory dysfunction. Intern Med 31:908-911
18. Noordam C, van der Burgt I, Sweep CG, Delemarre-Van de Waal HA, Sengers RC, Otten BJ 2001 Growth hormone (GH) secretion in children with Noonan syndrome: frequently abnormal without consequences for growth or response to GH treatment. Clin Endocrinol (Oxf) 54:53-59
19. Kelnar CJ 2000 Growth hormone therapy in Noonan syndrome. Horm Res 53(Suppl 1):77-81
20. Duncan WJ, Fowler RS, Farkas LG, Ross RB, Wright AW, Bloom KR, Huot DJ, Sondheimer HM, Rowe RD 1981 A comprehensive scoring system for evaluating Noonan syndrome. Am J Med Genet 10:37-50
21. Usher R, McLean F 1969 Intrauterine growth of live-born Caucasian infants at sea level: standards obtained from measurements in 7 dimensions of infants born between 25 and 44 weeks of gestation. J Pediatr 74:901-910
22. Sempé M, Pédron G, Roy-Pernot MP 1979 Croissance totale ou l'impératif de la taille. In: Sempé M, ed. Auxologie: méthodes et séquences. Paris: Théraplix; 25-36
23. Yoshida R, Miyata M, Nagai T, Yamazaki T, Ogata T 2004 A 3-bp deletion mutation of PTPN11 in an infant with severe Noonan syndrome including hydrops fetalis and juvenile myelomonocytic leukemia. Am J Med Genet 128A:63-66
24. Maheshwari M, Belmont J, Fernbach S, Ho T, Molinari L, Yakub I, Yu F, Combes A, Towbin J, Craigen WJ, Gibbs R 2002 PTPN11 mutations in Noonan syndrome type I: detection of recurrent mutations in exons 3 and 13. Hum Mutat 20:298-304
25. Yoshida R, Nagai T, Hasegawa T, Kinoshita E, Tanaka T, Ogata T 2004 Two novel and one recurrent PTPN11 mutations in LEOPARD syndrome. Am J Med Genet 130A:432-434
26. Lee WH, Raas-Rotschild A, Miteva M, Bolasco, G, Rein A, Gillis D, Vidaud D, Vidaud M, Villoutreix BO, Parfait B 2005 Noonan syndrome type I with PTPN11 3bp deletion-structure-function implications. Proteins 58:7-13
27. Tartaglia M, Niemeyer CM, Fragale A, Song X, Buechner J, Jung A, Hählen K, Hasle H, Licht JD, Gelb BD 2003 Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 34:148-150
28. Fragale A, Tartaglia M, Wu J, Gelb BD 2004 Noonan syndrome-associated SH2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation. Hum Mutat 23:267-277
29. Limal JM, Coutant R, Le Bouedec S 1999 Retard de croissance intra-utérin et principaux syndromes. In: Journées Parisiennes de pédiatrie. Paris: Flammarion Médecine-Science; 69-80
30. Stein-Gerlach M, Wallasch C, Ullrich A 1998 SHP-2, SH2-containing protein tyrosine phosphatase-2. Int J Biochem Cell Biol 30:559-566
31. Araki T, Nawa H, Neel BG 2003 Tyrosyl phosphorylation of Shp2 is required for normal ERK activation in response to some, but not all, growth factors. J Biol Chem 278:41677-41684
32. Ahmed ML, Foot AB, Edge JA, Lamkin VA, Savage MO, Dunger DB 1991 Noonan syndrome: abnormalities of the growth hormone/IGF-I axis and the response to treatment with human biosynthetic growth hormone. Acta Paediatr Scand 80:446-450
33. Romano AA, Blethen SL, Dana K, Noto RA 1996 Growth hormone treatment in Noonan syndrome: the national cooperative growth study experience. J Pediatr 128(Suppl):18-21
34. Bernardini S, Spadoni GL, Cianfarani S 1991 Growth hormone secretion in Noonan syndrome. J Pediatr Endocrinol Metab 4:217-221
35. Thomas BC, Stanhope R 1993 Long-term treatment with growth hormone in Noonan's syndrome. Acta Paediatr 82:852-855
36. Binder G, Neuer K, Ranke MB, Wittekindt NE 2005 PTPN11 mutations are associated with mild GH resistance in individuals with Noonan syndrome. J Clin Endocrinol Metab 90:5377-5381
37. Ferreira LV, Souza SA, Arnhold IJ, Mendonca BB, Jorge AA 2005 PTPN11 mutations and response to growth hormone therapy in children with Noonan syndrome. J Clin Endocrinol Metab 90:5156-5160
38. Clayton P 1999 The role of insulin-like growth factors in the diagnosis of growth hormone deficiency. In: Ranke MB, Wilton P, eds. Growth hormone therapy in KIGS-10 year's experience. Heidelberg, Leipzig: JA Barth Verlag; 53-64
39. Blum WF, Ranke MB, Kietzmann K, Gauggel E, Zeisel HJ, Bierich JR 1990 A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin-binding protein: its use for diagnosis of GH deficiency. J Clin Endocrinol Metab 70:1292-1298
40. Noordam C, van der Burgt I, Sengers RC, Delemarre-Van de Waal HA, Otten BJ 2001 Growth hormone treatment in children with Noonan's syndrome: four years results of a partly controlled trial. Acta Paediatr 90:889-894
41. Kirk JM, Betts PR, Donaldson MD, Dunger DB, Johnston DI, Kelnar CJH, Price DA, Wilton P 2001 Short stature in Noonan syndrome: response to growth hormone therapy. Arch Dis Child 84:440-443
42. Municchi G, Pasquino AM, Pucarelli I, Cianfarani S, Passeri F 1995 Growth hormone treatment in Noonan syndrome: report of four cases who reached final height. Horm Res 44:164-167
43. De Schepper J, Otten BJ, François I, Bourguignon JP, Craen M, Van der Burgt I 1997 Growth hormone therapy in pre-pubertal children with Noonan syndrome: first year growth response and comparison with Turner syndrome. Acta Paediatr 86:943-946
44. MacFarlane CE, Brown DC, Johnston LB, Patton MA, Dunger DB, Savage MO, McKeena WJ, Kelnar JH 2001 Growth hormone therapy and growth in children with Noonan's syndrome: results of 3 years' follow-up. J Clin Endocrinol Metab 86:1953-1956
45. Limal JM, Bonnet D, Hassan M, Leheup B, Lyonnet S, Cabrol S, Le Bouc Y 2002 Growth hormone therapy in children and adolescents with Noonan syndrome. Horm Res 58(Suppl 2):108 (Abstract)